全文获取类型
收费全文 | 7625篇 |
免费 | 567篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 188篇 |
妇产科学 | 94篇 |
基础医学 | 1063篇 |
口腔科学 | 131篇 |
临床医学 | 583篇 |
内科学 | 1926篇 |
皮肤病学 | 241篇 |
神经病学 | 761篇 |
特种医学 | 289篇 |
外科学 | 1078篇 |
综合类 | 43篇 |
预防医学 | 252篇 |
眼科学 | 146篇 |
药学 | 576篇 |
中国医学 | 15篇 |
肿瘤学 | 784篇 |
出版年
2024年 | 16篇 |
2023年 | 171篇 |
2022年 | 316篇 |
2021年 | 560篇 |
2020年 | 237篇 |
2019年 | 309篇 |
2018年 | 332篇 |
2017年 | 265篇 |
2016年 | 265篇 |
2015年 | 264篇 |
2014年 | 299篇 |
2013年 | 346篇 |
2012年 | 550篇 |
2011年 | 535篇 |
2010年 | 296篇 |
2009年 | 236篇 |
2008年 | 377篇 |
2007年 | 350篇 |
2006年 | 368篇 |
2005年 | 339篇 |
2004年 | 305篇 |
2003年 | 257篇 |
2002年 | 208篇 |
2001年 | 107篇 |
2000年 | 96篇 |
1999年 | 67篇 |
1998年 | 54篇 |
1997年 | 45篇 |
1996年 | 26篇 |
1995年 | 22篇 |
1994年 | 26篇 |
1993年 | 26篇 |
1992年 | 68篇 |
1991年 | 50篇 |
1990年 | 51篇 |
1989年 | 56篇 |
1988年 | 37篇 |
1987年 | 43篇 |
1986年 | 35篇 |
1985年 | 33篇 |
1984年 | 21篇 |
1983年 | 12篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1977年 | 11篇 |
1976年 | 13篇 |
1974年 | 10篇 |
1967年 | 11篇 |
排序方式: 共有8232条查询结果,搜索用时 15 毫秒
71.
Yuki Bekki Josep Marti Takeo Toshima Sara Lewis Amita Kamath Pamela Argiriadi William Simpson Lucas Facciuto Rahul S. Patel Ganesh Gunasekaran Edward Kim Thomas D. Schiano Marcelo E. Facciuto 《Surgery》2021,169(5):1044-1051
BackgroundPortal vein embolization before liver resection is considered the therapy of choice for patients with inadequate future liver remnants. The concept of radioembolization with Yttrium-90 to achieve the same goal has limited data.MethodsWe retrospectively compared patients who underwent portal vein embolization and Yttrium-90 lobectomy before resection of hepatocellular carcinoma in patients with chronic liver disease.ResultsSeventy-three patients underwent portal vein embolization and 22 patients underwent Yttrium-90. Forty-seven percent of patients before portal vein embolization required additional procedures for tumor control, and 27% of patients after Yttrium-90 required additional procedure to mainly induce further hypertrophy. Both therapies achieved the goal of future liver remnants >40%, but the degree of hypertrophy was significantly higher in Yttrium-90 patients (63% for Yttrium-90, 36% for portal vein embolization, P < .01). Tumor response was significantly better with Yttrium-90, achieving complete response in 50% of patients. Resectability rate was higher after portal vein embolization (85% for portal vein embolization, 64% for Yttrium-90, P = .03). Tumor progression was the most common reason precluding surgery. Complete tumor control was the reason not to pursue surgery in 18% of patients after Yttrium-90.ConclusionBoth preoperative portal vein embolization and Yttrium-90, increases liver resectability rates by inducing hypertrophy of future liver remnants in patients with hepatocellular carcinoma and chronic liver disease. Yttrium-90 lobectomy achieved better tumor control and provided more time to assess therapy response, optimizing the indication for surgery. 相似文献
72.
Yuki Ohya Masayoshi Tasaki Shintaro Hayashida Nobuhiro Katayama Toru Tsuchida Kazumi Kuriwaki Mitsuharu Ueda Yukihiro Inomata 《Transplantation proceedings》2021,53(4):1313-1316
BackgroundCarpal tunnel syndrome is the most common compression syndrome of the peripheral nerve. Transthyretin amyloidosis and dialysis-related β2-microglobulin amyloidosis are known causes of carpal tunnel syndrome.Case ReportA Japanese woman showed carpal tunnel syndrome 16 years after a domino liver transplantation (DLT) from the donor with hereditary transthyretin amyloidosis. DLT indication was congenital extrahepatic portosystemic shunt, and the patient had been put on maintenance hemodialysis because of chronic kidney disease 6 years before DLT. Moreover, the amyloid precursor protein of the patient was histologically confirmed not to be β2-microglobulin, but transthyretin.ConclusionsThe existence of amyloid was speculated when the patient who underwent DLT from hereditary transthyretin amyloidosis showed carpal tunnel syndrome. Additionally, elucidating the amyloid precursor protein when the patient has another cause of amyloidosis is necessary. 相似文献
73.
Yuki Matsushita Angel Ka Yan Chu Wanida Ono Joshua D Welch Noriaki Ono 《Journal of bone and mineral research》2021,36(6):1145-1158
Bone marrow houses a multifunctional stromal cell population expressing C-X-C motif chemokine ligand 12 (CXCL12), termed CXCL12-abundant reticular (CAR) cells, that regulates osteogenesis and adipogenesis. The quiescent pre-adipocyte-like subset of CXCL12+ stromal cells (“Adipo-CAR” cells) is localized to sinusoidal surfaces and particularly enriched for hematopoiesis-supporting cytokines. However, detailed characteristics of these CXCL12+ pre-adipocyte-like stromal cells and how they contribute to marrow adipogenesis remain largely unknown. Here we highlight CXCL12-dependent physical coupling with hematopoietic cells as a potential mechanism regulating the adipogenic potential of CXCL12+ stromal cells. Single-cell computational analyses of RNA velocity and cell signaling reveal that Adipo-CAR cells exuberantly communicate with hematopoietic cells through CXCL12-CXCR4 ligand-receptor interactions but do not interconvert with Osteo-CAR cells. Consistent with this computational prediction, a substantial fraction of Cxcl12-creER+ pre-adipocyte-like cells intertwines with hematopoietic cells in vivo and in single-cell preparation in a protease-sensitive manner. Deletion of CXCL12 in these cells using Col2a1-cre leads to a reduction of stromal-hematopoietic coupling and extensive marrow adipogenesis in adult bone marrow, which appears to involve direct conversion of CXCL12+ cells to lipid-laden marrow adipocytes without altering mesenchymal progenitor cell fates. Therefore, these findings suggest that CXCL12+ pre-adipocyte-like marrow stromal cells prevent their premature differentiation by maintaining physical coupling with hematopoietic cells in a CXCL12-dependent manner, highlighting a possible cell-non-autonomous mechanism that regulates marrow adipogenesis. © 2021 American Society for Bone and Mineral Research (ASBMR). 相似文献
74.
Naoki Fujita Shingo Hatakeyama Kazutaka Okita Masaki Momota Takuma Narita Yuki Tobisawa Tohru Yoneyama Hayato Yamamoto Atsushi Imai Hiroyuki Ito Takahiro Yoneyama Yasuhiro Hashimoto Kazuaki Yoshikawa Chikara Ohyama 《Urologic oncology》2021,39(3):191.e9-191.e16
ObjectivesTo investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who underwent adjuvant induction bacillus Calmette-Guérin (BCG) therapy after transurethral resection of bladder tumor (TURBT).Materials and MethodsWe conducted a multi-institutional retrospective study assessing 209 patients with high-risk NMIBC who underwent TURBT and subsequent adjuvant induction BCG therapy from December 1998 to April 2019. Patients were divided into 2 groups: those with preoperative estimated glomerular filtration rate (eGFR) ≥ 60 ml/min/1.73 m2 (non-CKD group), and those with eGFR < 60 ml/min/1.73 m2 (CKD group). Primary endpoints were intravesical recurrence-free survival (RFS) and muscle-invasive bladder cancer (MIBC)-free survival. Background-adjusted multivariate analyses with the inverse probability of treatment weighting (IPTW) method using the propensity score were performed to evaluate the impact of CKD on intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. Moreover, multivariable analyses were performed to assess the impact of CKD on intravesical recurrence and MIBC progression, adjusting for the competing risk of death using the Fine-Gray competing risk regression model.ResultsMedian age and follow-up period after TURBT were 72 years and 45 months, respectively. Of 209 patients, 71 (34%) were diagnosed with CKD before TURBT. Background-adjusted multivariate analyses with the IPTW method indicated that CKD was significantly associated with shorter intravesical RFS, MIBC-free survival, metastasis-free survival, cancer-specific survival, and overall survival. In the Fine-Gray competing risk regression model, CKD showed significantly higher probabilities of intravesical recurrence and MIBC progression, with an adjusted subdistribution hazard ratio of 1.886 (95% confidence interval 1.069–3.330, P = 0.028) and 3.740 (95% confidence interval 1.060–13.20, P = 0.040), respectively.ConclusionsCKD presents a risk factor of poor oncological outcomes in patients with high-risk NMIBC who underwent adjuvant induction BCG therapy after TURBT. 相似文献
75.
76.
Wada Takehiko Ishimoto Takuji Nakaya Izaya Kawaguchi Takehiko Sofue Tadashi Shimizu Sayaka Kurita Noriaki Sasaki Sho Nishiwaki Hiroki Koizumi Masahiro Saito Shoji Nishibori Nobuhiro Oe Yuji Yoshida Mai Miyaoka Yoshitaka Akiyama Shin’ichi Itano Yuya Okazaki Masaki Ozeki Takaya Ichikawa Daisuke Oguchi Hideyo Kohsaka Satoshi Kosaka Shiho Kataoka Yuki Shima Hideaki Shirai Sayuri Sugiyama Kazuhiro Suzuki Tomo Son Daisuke Tanaka Tomomi Nango Eishu Niihata Kakuya Nishijima Yoko Nozu Kandai Hasegawa Midori Miyata Rei Yazawa Masahiko Yamamoto Yoshihiro Yamamoto Ryohei Shibagaki Yugo Furuichi Kengo Okada Hirokazu Narita Ichiei 《Clinical and experimental nephrology》2021,25(12):1277-1285
Clinical and Experimental Nephrology - 相似文献
77.
Kosuke Ebina Hideki Tsuboi Yoshio Nagayama Masafumi Kashii Shoichi Kaneshiro Akira Miyama Hiroyuki Nakaya Yasuo Kunugiza Makoto Hirao Gensuke Okamura Yuki Etani Kenji Takami Atsushi Goshima Taihei Miura Ken Nakata Seiji Okada 《Joint, bone, spine : revue du rhumatisme》2021,88(5):105219
ObjectivesTo investigate the effects of prior treatment and determine the predictors of a 12-month treatment response of romosozumab (ROMO) in 148 patients with postmenopausal osteoporosis.MethodsIn this prospective, observational, and multicenter study, treatment naïve patients (Naïve; n = 50) or patients previously treated with bisphosphonates (BP; n = 37) or denosumab (DMAb; n = 45) or teriparatide (TPTD; n = 16) (mean age, 75.0 years; T-scores of the lumbar spine [LS] ?3.2 and total hip [TH] ?2.6) were switched to ROMO due to insufficient effects of prior treatment. Bone mineral density (BMD) and serum bone turnover markers were evaluated for 12 months.ResultsAt 12 months, changes in LS BMD were Naïve (18.2%), BP (10.2%), DMAb (6.4%), and TPTD (11.2%) (P < 0.001 between groups) and changes in TH BMD were Naïve (5.6%), BP (3.3%), DMAb (0.6%), and TPTD (4.4%) (P < 0.01 between groups), respectively. In all groups, the LS BMD significantly increased from baseline at 6 and 12 months, although only the DMAb group failed to obtain a significant increase in TH BMD during 12-month treatment. Mean values of N-terminal type I procollagen propeptide (PINP; μg/L) from baseline → 1 month → 12 months were Naïve (67.9 → 134.1 → 51.0), BP (32. 2 → 81.7 → 40.9), DMAb (30.4 → 56.2 → 75.3), and TPTD (97.4 → 105.1 → 37.1), and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b; mU/dL) were Naïve (500.4 → 283.8 → 267.1), BP (273.4 → 203.1 → 242.0), DMAb (220.3 → 246.1 → 304.8), and TPTD (446.6 → 305.1 → 235.7), respectively. Multiple regression analysis revealed that the significant predictors of BMD change at 12 months were difference of prior treatment (r = ?2.8, P < 0.001) and value of PINP at 1 month (r = 0.04, P < 0.01) for LS, and difference of prior treatment (r = ?1.3, P < 0.05) and percentage change of TRACP-5b at 1 month (r = ?0.06, P < 0.05) for TH.ConclusionsThe early effects of ROMO on LS and TH BMD increase at 12 months were significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. 相似文献
78.
Go Anan Hiromichi Iwamura Jotaro Mikami Yuki Kohada Jun Ito Yasuhiro Kaiho Makoto Sato 《Translational andrology and urology》2021,10(2):775
BackgroundHolmium laser enucleation of the prostate (HoLEP) has been a widely utilized minimally invasive surgical procedure for benign prostate hyperplasia. The current study aimed to compare surgical outcomes and King’s Health Questionnaire (KHQ) assessment scores following HoLEP between younger men and those aged ≥75 years.MethodsThis prospective single-center study compared perioperative complications, postoperative urinary conditions, and KHQ scores (nine categories) between men aged ≥75 years (group A) and men aged <75 years (group B) before and 1, 3, and 6 months after surgery.ResultsA total of 100 patients were included for analysis (group A, n=38 and group B, n=62). No differences in patient backgrounds, perioperative complications, such as perioperative decrease in hemoglobin, postoperative fever, postoperative indwelling catheterization duration, or postoperative hospitalization duration, and KHQ were observed between both groups. Both groups showed significantly better International Prostate Symptom Scores, quality of life, maximum urinary flow rate, and postvoid residual volume 1, 3, and 6 months after HoLEP compared to their respective preoperative levels (P<0.01). Regarding KHQ categories, both groups showed significantly better general health perceptions, impact on life, emotions, and sleep/energy 1 month after HoLEP; role limitations, physical limitations, and social limitations 3 months after HoLEP; and personal relationships and incontinence severity measures 6 months after HoLEP compared to their respective preoperative levels (P<0.05).ConclusionsHoLEP could be safe and effective even for men aged ≥75 years, comparing complications, urinary condition, and KHQ scores. 相似文献
79.
Masayuki Tomioka Tohru Yoneyama Yuki Tobisawa Kota Kawase Chie Nakai Manabu Takai Daiki Kato Koji Iinuma Keita Nakane Kosuke Mizutani Yasuhiro Hashimoto Takuya Koie 《Translational andrology and urology》2021,10(3):1192
BackgroundAlthough the patients with muscle-invasive bladder cancer (MIBC) generally have poor prognosis, the utility of these biomarkers for the prediction of oncological outcomes in MIBC has not been completely explored. Ghrelin regulates processes associated with cancer, including cell proliferation, apoptosis, cell migration, cell invasion, and angiogenesis. Thus, we aimed to evaluate the impact of serum ghrelin levels on survival in MIBC.MethodsIn this study, we reviewed the clinical and pathological records of 56 patients who were diagnosed with MIBC between November 2015 and November 2019 at Gifu and Hirosaki University Hospitals. We focused on 27 patients who had received chemotherapy and collected blood samples before and after chemotherapy. Blood samples were collected before chemotherapy and after completing two cycles of chemotherapy. Serum acyl (AG) and desacyl ghrelin (DG) were measured using AG and DG enzyme-linked immunosorbent assay kits (SCETI, Tokyo, Japan), respectively.ResultsThe 3-year overall and progression-free survival (PFS) rates were 82.9% and 68.3%, respectively. According to the AG level after chemotherapy, the 3-year PFS rates were 77.5% and 53.0% in patients with AG levels ≥1.34 and <1.34 pg/mL, respectively (P=0.038). With regard to DG levels after chemotherapy, the 3-year PFS rates were 90.9% and 43.3% in patients with DG levels <92.3 and ≥92.3 pg/mL, respectively (P=0.039). On multivariate analysis, serum AG levels were significantly associated with PFS.ConclusionsThis study suggested the usefulness of the ghrelin as a prognostic predictor of PFS in patients with MIBC. 相似文献
80.
Yuki Tajika Tohru Murakami Mahito Sato Fumitaka Kubota Hiroshi Yorifuji 《Developmental dynamics》2008,237(7):1886-1892
Vesicle-associated membrane protein 2 (VAMP2) is a member of the SNARE family of proteins that regulate the intracellular vesicle fusion process. This study investigated the developmental expression of VAMP2 in the rat embryo. In the trunk, VAMP2 was primarily found in the heart on embryonic day (E) 10. On E12.5, VAMP2 expression was found in nerve fibers, somites, and heart. In somites, epithelial cells in the dorsomedial lip, and elongated myoblasts in myotome were positive for VAMP2. On E16.5, VAMP2 was expressed in the heart, nerve fibers, and skeletal muscles. In skeletal muscles, multinuclear myotubes were positive for VAMP2. In the head, where muscles are derived both from somitic and non-somitic origin, VAMP2 was found in myotubes of the extrinsic ocular muscles and masseter muscle on E16.5. These findings suggest the involvement of VAMP2 in the development of skeletal muscles of somitic and non-somitic origins. 相似文献